Cabaletta Bio, Inc.
CABAHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cabaletta Bio, Inc. (CABA) is listed under Biotechnology. At a $616.3M market cap, Cabaletta Bio, Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Market Cap
$616.3M
Beta
3.17
P/E (TTM)
—
P/E (Fwd)
-2.57
EPS (TTM)
$-1.78
EPS (Fwd)
$-1.47
ROE
-156.0%
ROA
-71.6%
Cash
$116.6M
Total Debt
$26.4M
Free CF
-$90.8M
52W Change
83.5%
Annual Financials
Cash vs Debt
Cabaletta Bio, Inc. holds $116.6M in cash against $26.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$90.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -156.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 3.17 means CABA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CABA.